Equity Profile

RVMD

Revolution Medicines, Inc.

Health CareBiotechnology$43.3B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer and other serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and will indicate how well it is managing its expenses relative to its revenues.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's market demand and overall business health, especially in the competitive biotech industry.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RVMD Q2-2026 Earnings Preview

Context

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer and other serious diseases. With a market cap of $43 billion, it plays a significant role in the health care sector, particularly in advancing innovative treatments that could improve patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

In Q1-2026, Revolution Medicines reported an EPS of -$2.29, which was worse than the expected -$1.83, resulting in a 2.62% increase in stock price the next day. The company continues to face challenges in meeting earnings expectations.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's innovative pipeline but are wary due to recent earnings misses.

Bull Case

If the company can demonstrate significant progress in its clinical trials or provide positive updates on its drug pipeline, it could lead to a strong stock performance.

Bear Case

Conversely, if the company reports another earnings miss or delays in its clinical trials, it could further erode investor confidence and negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the clinical trials for key drug candidates?

Investors will closely watch for updates that could indicate the potential for future revenue and market success.

How does management plan to address the recent earnings misses?

Understanding management's strategy for improving financial performance will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of recent clinical trial successes, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing in a 7.42% move, indicating expectations of volatility that may not align with the actual performance.

Recent trends show that the stock has often reacted positively to clinical updates, despite earnings misses.

Key Risk

If clinical trial results exceed expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential of Revolution Medicines' pipeline against its recent struggles to meet earnings expectations.

Bull Confirmed If

A positive update on clinical trial results or a significant reduction in EPS loss could confirm the bull case.

Bear Confirmed If

Continued earnings misses or negative trial results would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.42%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±7.4% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

51.3%

Calls (25K)P/C Ratio: 0.45Puts (37K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations, history suggests a potential stock increase of around 2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting ongoing investor caution.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around 0.14% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any changes to the company's strategic direction or focus areas.
3Management's commentary on cost management and future profitability.
4Insights into partnerships or collaborations that could enhance the pipeline.
5Guidance on expected timelines for product launches or regulatory approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer and other serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and will indicate how well it is managing its expenses relative to its revenues.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's market demand and overall business health, especially in the competitive biotech industry.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RVMD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's innovative pipeline but are wary due to recent earnings misses.

Bull Case

If the company can demonstrate significant progress in its clinical trials or provide positive updates on its drug pipeline, it could lead to a strong stock performance.

Bear Case

Conversely, if the company reports another earnings miss or delays in its clinical trials, it could further erode investor confidence and negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the clinical trials for key drug candidates?

Investors will closely watch for updates that could indicate the potential for future revenue and market success.

How does management plan to address the recent earnings misses?

Understanding management's strategy for improving financial performance will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of recent clinical trial successes, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing in a 7.42% move, indicating expectations of volatility that may not align with the actual performance.

Recent trends show that the stock has often reacted positively to clinical updates, despite earnings misses.

Key Risk

If clinical trial results exceed expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential of Revolution Medicines' pipeline against its recent struggles to meet earnings expectations.

Bull Confirmed If

A positive update on clinical trial results or a significant reduction in EPS loss could confirm the bull case.

Bear Confirmed If

Continued earnings misses or negative trial results would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.42%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±7.4% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

51.3%

Calls (25K)P/C Ratio: 0.45Puts (37K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations, history suggests a potential stock increase of around 2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting ongoing investor caution.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around 0.14% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any changes to the company's strategic direction or focus areas.
3Management's commentary on cost management and future profitability.
4Insights into partnerships or collaborations that could enhance the pipeline.
5Guidance on expected timelines for product launches or regulatory approvals.